At the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), researchers presented data showing that Xultophy (insulin degludec/liraglutide; Novo Nordisk) significantly decreased the number of risk factors associated with increased risk of cardiovascular disease (CVD) in patients with type 2 diabetes, as compared to basal insulin.
The data came from a post-hoc analysis of two randomized-controlled trials that compared Xultophy to insulin degludec (DUAL II) and to insulin glargine U100 (DUAL V), given with metformin for 26 weeks. At baseline, study patients did not achieve glycemic control with HbA1c levels ranging from 7.0–10.0% and basal insulin use ranging from 20–50 Units.
The data showed Xultophy-treated patients had significantly lower systolic blood pressure, lower total cholesterol, and lower low-density lipoprotein (LDL) cholesterol vs. patients treated with basal insulin (insulin glargine U100 or insulin degludec). The authors also reported significant and favorable weight changes among Xultophy-treated patients vs. those treated with basal insulin. Patients treated with Xultophy also exhibited a small but statistically significant increase in pulse.
Xultophy is a single-injection combination of a long-acting insulin and a GLP-1 receptor agonist. It is approved to treat adults with type 2 diabetes mellitus to improve glycemic control in combination with oral glucose-lowering drugs when they alone or with basal insulin do not provide adequate glycemic control.
Xultophy is supplied as a solution for subcutaneous injection containing 100 Units/mL insulin degludec and 3.6mg/mL liraglutide. It is available as 3mL prefilled pens in 5-count cartons.
For more information call (800) 727-6500 or visit Xultophy10036.com.